

University of Groningen

Hydrogen Sulfide

Abdulle, Amaal Eman; van Goor, Harry; Mulder, Douwe J.

Published in:
International Journal of Molecular Sciences

DOI:
[10.3390/ijms19124121](https://doi.org/10.3390/ijms19124121)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Abdulle, A. E., van Goor, H., & Mulder, D. J. (2018). Hydrogen Sulfide: A Therapeutic Option in Systemic Sclerosis. *International Journal of Molecular Sciences*, 19(12), [4121]. <https://doi.org/10.3390/ijms19124121>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Review

Hydrogen Sulfide: A Therapeutic Option in Systemic Sclerosis

Amaal Eman Abdulle ^{1,*} , Harry van Goor ^{2,†} and Douwe J. Mulder ^{1,†}

¹ Department of Internal Medicine, Division Vascular Medicine, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands; d.j.mulder@umcg.nl

² Department of Pathology and Medical Biology, Section Pathology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands; h.van.goor@umcg.nl

* Correspondence: a.aman.abdulle@umcg.nl; Tel.: +31-50-361-3400; Fax: +31-50-361-3312

† These authors contributed equally to this work.

Received: 1 November 2018; Accepted: 17 December 2018; Published: 19 December 2018



Abstract: Systemic sclerosis (SSc) is a lethal disease that is characterized by auto-immunity, vascular injury, and progressive fibrosis of multiple organ systems. Despite the fact that the exact etiology of SSc remains unknown, oxidative stress has been associated with a large range of SSc-related complications. In addition to the well-known detrimental properties of reactive oxygen species (ROS), gasotransmitters (e.g., nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S)) are also thought to play an important role in SSc. Accordingly, the diverse physiologic actions of NO and CO and their role in SSc have been previously studied. Recently, multiple studies have also shown the importance of the third gasotransmitter H₂S in both vascular physiology and pathophysiology. Interestingly, homocysteine (which is converted into H₂S through the transsulfuration pathway) is often found to be elevated in SSc patients; suggesting defects in the transsulfuration pathway. Hydrogen sulfide, which is known to have several effects, including a strong antioxidant and vasodilator effect, could potentially play a prominent role in the initiation and progression of vasculopathy. A better understanding of the actions of gasotransmitters, like H₂S, in the development of SSc-related vasculopathy, could help to create early interventions to attenuate the disease course. This paper will review the role of H₂S in vascular (patho-)physiology and potential disturbances in SSc. Moreover, current data from experimental animal studies will be reviewed. Lastly, we will evaluate potential interventional strategies.

Keywords: gasotransmitters; systemic sclerosis; vasculopathy; endothelial injury; therapeutic intervention

1. Introduction

Systemic sclerosis (SSc) is a severe progressive fibrotic connective tissue disease that often affects multiple systems [1,2]. The disease is characterized by chronic inflammation, autoimmunity, and vasculopathy, which all lead to substantial disability, high morbidity and mortality rates, and a decreased quality of life [3]. Reported prevalence rates for SSc range from 30 to 300 cases per 1 million persons, and the age of onset is approximately 50 years [4–6]. A variety of disabling complications (e.g., skin fibrosis, gastrointestinal dysmotility, scleroderma renal crisis (SRC), and lung involvement) occur in the early stages of the disease. Despite many efforts, the pathogenesis still remains unknown and effective disease-modifying treatment is currently unavailable. In addition, current treatment options (such as immunosuppressants) can cause a variety of adverse effects, including bone marrow

depression, impaired hepatic and renal function, and infections. Therefore, new (low-risk) therapy options need to be found.

Endothelial dysfunction is a main event in the pathogenesis of SSc [7], and the vascular bed is a major target for immune-inflammatory injury. The vascular injury (i.e., vasculopathy) is characterized by the dysfunction of endothelial cells (ECs), inflammation, and vascular wall remodeling [8]. Raynaud's phenomenon (RP), which manifests as episodic vasospastic events leading to the discoloration of the extremities, is the most recognizable and primary clinical sign that reflects the vascular injury [9]. Raynaud's phenomenon often precedes visceral disease by several years and, therefore, RP is a crucial part of the important criteria for the diagnosis of early SSc (VEDOSS criteria) [2]. Following RP, the vasculopathy often progresses and becomes clinically evident as necrotic lesions of the fingertips (i.e., digital ulcerations), SRC, and pulmonary arterial hypertension (PAH) [2]. A current hypothesis is that early detection of SSc may allow an adequate start of appropriate therapeutic regimen to arrest disease progression.

The exact etiology of SSc remains unknown, but some studies have suggested that gasotransmitters play an important role in its pathogenesis. Gasotransmitters, which are endogenously produced gaseous signaling molecules, play a major role in several physiological processes, ranging from vessel tone regulation, modulation of the immune system, and protection against oxidative stress [10,11]. To date, three main gasotransmitters have been discovered, namely, hydrogen sulfide (H_2S), carbon monoxide (CO), and nitric oxide (NO) [12]. As these gases perform critical roles, a deviation of their normal level may be associated with the occurrence of several diseases ranging from neurodegenerative diseases to auto-immune diseases. Interestingly, some reports have stated that SSc patients show a decreased level of H_2S . Moreover, the beneficial effects of H_2S in a scleroderma-like experimental animal study have also been proven. Therefore, an assessment of the role played by H_2S in SSc-related vasculopathy could lead to a better understanding of this disease, which could subsequently help to create early interventions to attenuate the disease course. This review focuses on the role of H_2S in the pathogenesis of SSc-related vasculopathy in relation to its functional properties in the healthy vascular system. Furthermore, we evaluate the effects of H_2S -based therapeutic interventions.

2. Role of Nitric Oxide and Carbon Monoxide in Systemic Sclerosis

The role of NO in SSc has been extensively discussed elsewhere [13–18], and, therefore, will be shortly mentioned here. The free radical gas NO is synthesized from the amino acid L-arginine by a family of isoenzymes, termed nitric oxide synthases (NOS) [19,20]. There are three known isoforms, namely endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). Endothelial NOS is the major isoform regulating vascular function, and it is primarily expressed in ECs, cardiomyocytes, neurons, and hepatocytes [21]. Induction of iNOS occurs usually in response to infection and chronic inflammation [22], and it is especially found in immunological cells, such as macrophages and neutrophils [23,24]. Nitric oxide may stimulate soluble guanylyl cyclase (sGC) in vascular smooth muscle cells (VSMCs) to induce the formation of cyclic guanosine monophosphate (cGMP) [25,26]. Subsequently, the formation of cGMP activates protein kinase G (PKG) [26], which leads to the reduction of cytosolic Ca^{2+} and reduction of the sensitivity of smooth muscle cells (SMCs) to Ca^{2+} . As a result of this process, the intracellular concentration of calcium decreases and vasorelaxation is promoted [11,27,28]. Endothelial dysfunction is believed to be a main target in SSc. Although several mechanisms have been proposed that play an important role in this process, the exact role of NO still remains incompletely understood as both protective and harmful effect of NO have previously been described [13]. It was previously suggested that a decreased release of NO, which may lead to impaired endothelial-dependent vasodilatation, might play an important role in the pathogenesis of the SSc-related vasculopathy. In support, several studies reported a decreased level of NO release [29,30]. Subsequently, this may promote the development of vasculopathy by inducing recurrent RP attacks, increasing vascular wall thickness, and by enhancing the platelet aggregation. Moreover, NO is also believed to protect the endothelium from oxidative stress by acting as a free radical scavenger, and

inhibiting lipid peroxidation [31,32]. In contrast, NO is also believed to have several harmful effects. For instance, it was previously reported that iNOS expression, which is often considered as a harmful enzyme [33], is up-regulated in affected skin, fibroblast, and endothelial cells [14,34]. Interestingly, it has been proposed that with the progression of SSc the NO production, which is primarily produced by eNOS in the early stages of the disease, is replaced by iNOS in endothelial cells and fibroblast [14,34]. This finding may indicate that the increased levels of NO, which were previously reported in SSc [35], may be induced by the increased expression of mainly iNOS. These conflicting results indicate that the exact role of NO in SSc still remains complex, and further studies should be conducted in order to clarify the role of NO in the pathogenesis of SSc.

Although the role of CO in SSc is less known, previous studies have suggested that CO may play an important role in several vascular diseases with a similar pathology as SSc. Carbon monoxide is generated by haem oxygenases (HO), namely HO-1 and HO-2, which are both expressed in the heart and blood vessels, as a result of the degradation of haem [36,37]. The oxidative degradation of haem, catalyzed by HO, results in the formation of iron (Fe^{2+}), CO, and biliverdin [27]. Biliverdin is further converted into biologically important antioxidant bilirubin. Comparable to the formation of NO, this reaction requires O_2 and nicotinamide adenine dinucleotide phosphate (NADPH) as cofactors. Similar to NO, CO is also thought to have important vasoregulatory effects. For instance, CO is thought to induce vasorelaxation in large vessels (e.g., aorta) by activating sGC in VSMCs, which leads to the formation of cGMP [27]. In smaller vessels, CO is thought to promote vasorelaxation by affecting calcium-activated potassium channels in VSMCs [38]. In contrast to these findings, other studies failed to demonstrate the vasodilatory effect of CO on cerebral arteries [39,40], or even reported on the vasoconstricting effect of CO [41], presumably by negatively affecting eNOS activity [28,42]. In addition to its vasoregulatory effect, CO is also believed to have several anti-inflammatory, anti-apoptotic, and pro-apoptotic effects. For instance, it was previously shown that CO may act as an anti-apoptotic agent in ECs, and, thus, prevent cell injury through Akt activation, and by affecting p38 mitogen-activated protein kinases (MAPK) signaling pathway [43–45]. In contrast, CO can also arrest fibroblast proliferation [46] as well as VSMC proliferation [47]. Considerable evidence supports a protective role for the HO-1/CO system in several cardiovascular diseases (e.g., atherosclerosis, myocardial infarction, and hypertension). The protective effect of CO in these diseases is thought to be associated with the prevention of oxidative stress-induced endothelial damage [43], increased production of bilirubin [48], increased stability of HIF-1 α [49], and improved vasorelaxation [38]. Given the fact that some of these diseases may share a common pathogenesis, it could be postulated that CO might also have several beneficial effects in SSc patients.

3. The Role of Hydrogen Sulfide in Vascular Biology

3.1. Production of H_2S

Hydrogen sulfide is an evolutionary gaseous signaling molecule, and the earliest forms of life on earth depended on sulfur as an energy source and not oxygen. Only at the time that oxygen levels started to rise on earth, sulfide syntrophy largely disappeared. It was not until the last couple of decades that H_2S was rediscovered in mammals as being an endogenously produced gasotransmitter, and its important functions have now been increasingly recognized [50]. Although high concentrations of H_2S are believed to be toxic, the enhancement of its physiological effects has been proven to be beneficial in several diseases.

This endogenous gasotransmitter is enzymatically generated by four enzymes, namely cystathionine β -synthase (CBS), cystathionine γ -lyase (CSE), cysteine aminotransferase (CAT), in conjunction with 3-mercaptopyruvate sulfurtransferase (3MST) [51–54]. These H_2S producing enzymes are expressed in various vascular cell types (e.g., ECs and vascular smooth muscle cells (VSMCs)). Both CBS and CSE are found in the cytosol, whereas 3MST is mainly found in the mitochondria [55]. In ECs, CSE activity, which is strictly regulated by intracellular Ca^{2+} concentrations, is the main

contributor to H_2S production [56]. Both of the pyridoxal-5 phosphate-dependent enzymes (i.e., CSE and CBS) play an important role in the transsulfuration pathway [55,57]. During this process, homocysteine is converted into cystathionine by CBS, which is then converted by CSE to L-cysteine (Figure 1). Ammonium and pyruvate are also produced during this process. However, their exact roles in cellular functions remain not well clarified [58]. Although CSE, CBS, 3MST, and CAT are essential for the formation of H_2S , it should be realized that these enzymes are also responsible for a number of other reactions that do not lead to the production of H_2S [57]. Although H_2S can also be produced through several non-enzymatic processes (e.g., through reductive chemistry of various forms of sulfur, including thiosulfate, thiocystine, and sulfite), these pathways are less well understood and only account for a small portion of H_2S production [59].




Figure 1. Schematic presentation of the production and function of hydrogen sulfide. Cystathionine β -synthase (CBS); cystathionine γ -lyase (CSE); cysteine aminotransferase (CAT); d-Amino acid oxidase (DAO); 3-mercaptopyruvate sulfurtransferase (3MST); reactive oxygen species (ROS); vascular smooth muscle cells (VSMCs); ATP-sensitive potassium channel (K-ATP); cyclic adenosine monophosphate (cAMP); Up-arrows represent up-regulations, down-arrows represent down-regulation.

The concentration of H_2S in human blood was previously estimated to range from 10–100 μM [60,61], however, recent studies using more precise methods reported values of only 14–15 nanomolar [62,63]. Moreover, it should be noted that the measured H_2S concentration is strongly dependent on the age of the subject and the method used [64].

Hydrogen sulfide can be quickly eliminated and it is initially oxidized to thiosulfate. Following this process, thiosulfate is further converted into sulfite and sulfate (Figure 1). Other routes of elimination include binding to methemoglobin and cytosolic methylation [65]. Given the fact that thiosulfate can easily be converted back into H_2S , this sodium salt is often considered as a H_2S donor. Sulfate is considered an important end-product of H_2S metabolism. In humans, the majority of the circulatory inorganic sulfate is generated from the sulfur containing amino acids (SAA) methionine and cysteine, which are both derived from dietary protein [66,67]. However, because of the beneficial effects of H_2S , it can also be hypothesized that the higher intake of SAAs contributes to the formation of H_2S , and thereby, beneficially influences the cardiovascular profile, and, as a result, patient survival [68,69]. Therefore, sulfate levels could also possibly serve as an indication of H_2S production. However, in order to understand the role of this important gasotransmitter in pathophysiology of many vascular diseases (including SSc), one has to comprehend the role that it plays in normal vascular biology.

3.2. Vascular Biology

3.2.1. Vascular Tone Regulation

Regulation of the vascular tone is crucial in maintaining adequate blood flow and tissue oxygenation to the organs. This balance in vasodilation and vasoconstriction is strictly regulated by various factors, among which H_2S plays an important role. Hydrogen sulfide is believed to have a biphasic effect on the vascular tone, through the mediation of both vasoconstriction and vasodilation. Lower concentrations of H_2S are believed to induce vasoconstriction. This postulation is supported by the fact that the reversal of the vasodilatory effect of acetylcholine and histamine, which are both NO-dependent vasodilators, was achieved after treatment with H_2S in lower concentrations ($<100 \mu\text{M}$) [70]. In addition, even very low concentrations of $30 \mu\text{M}$ were found to induce a strong vasoconstrictive effect. This vasoconstrictive effect is believed to be induced through the inactivation of NO, down-regulation of eNOS, increase in reactive oxygen species (ROS) production, and through the decrease of intracellular cyclic adenosine monophosphate (cAMP) in VSMCs [54,71]. Moreover, it was previously demonstrated that the vasoconstrictive effect of H_2S was endothelial dependent in phenylephrine-precontracted rat aorta [72]. This experimental study demonstrated that the contractile effect of H_2S disappeared after the removal of the endothelium. Interestingly, the contractile activity of H_2S was found to be more prominent in the absence of oxygen [73].

Conversely, higher levels are believed to promote vasodilation by affecting K_{ATP} channels, Ca^{2+} channels, and the $\text{Cl}^-/\text{HCO}_3^-$ exchanger (Figure 2). In particular, H_2S leads to the hyperpolarization of K_{ATP} channels in VSMCs, which reduces intracellular Ca^{2+} and leads to the relaxation of smooth muscle cells [74]. However, given the fact that glibenclamide, which is a K_{ATP} inhibitor, only partially prevented vasodilation, it has to be noted that the vasodilatory effect of H_2S is not solely exerted through its effect on the K_{ATP} channels [75]. In addition, H_2S also induces vasodilation by modulating K_v7 channels in VSMCs [75], and by affecting K_{Ca} channels [76]. Moreover, the inhibition of cytochrome c oxidase by H_2S may lead to a decrease in cellular ATP levels and activate K_{ATP} channels, which subsequently promotes vasodilation [77,78]. In contrast to the vasoconstrictive effect of H_2S , vasodilation is thought to be promoted by the activation of eNOS and stimulation of NO-release [79]. In addition, it has been shown that the intermediates that form due to the NO- H_2S crosstalk might also play an important role in this process. Hydrogen sulfide has been proven to reduce the blood pressure in various experimental models. More particularly, several experimental animal studies in mice have shown a reduction of the blood pressure after the administration of both systemic and local H_2S donors (e.g., NaHS) [80–82]. More recently, it has been reported that H_2S and NO, which are both key regulators in various physiological functions, are able to interact with each other and form intermediates with important physiological functions [83]. For instance, H_2S was found to reduce oxidized NO forms, and thereby form several intermediate products (e.g., SSNO^- , HSNO , HNO , and HSSH), which are highly redox-sensitive [83]. Therefore, it has become increasingly clear that the

interactions between NO and H₂S may have a significant effect on the regulation of the vascular tone. In support, Hosoki et al. (1997) demonstrated that H₂S can induce a stronger vasorelaxant effect in the presence of an NO donor [84]. Another study reported that HNO might induce vasodilation by activating the cGMP-dependent pathway [85]. A recent review describes these interactions between gasotransmitters in the redox system as the “redox signaling interactome”, and these interactions may lead to targets for new therapeutic interventions [86].




Figure 2. Physiological effects of intracellular hydrogen sulfide production in vascular smooth muscle cells and endothelial cells. Vascular endothelial growth factor receptor 2 (VEGFR-2); Acetylcholine receptor (AchR); Cysteine (Cys); endothelial nitric oxide synthases (eNOS); black solid arrows represent a direct effect, the black dotted arrows represent a direct effect on a different cell, and the green T-bar represents the inhibitory effect of hydrogen sulfide.

3.2.2. Cell Proliferation and Angiogenesis

Hydrogen sulfide was previously reported to stimulate EC proliferation, which is an essential part of the initial angiogenic response. Two independent studies reported that H₂S, in various concentration (ranging from 1–600 μ M), increased the proliferation of human umbilical vein endothelial cells (HUVECs) and of transformed endothelial cells by 30–100% [87,88]. Moreover, H₂S, at low concentrations (10–20 μ mol/L), promotes EC migration and adhesion, which may further stimulate angiogenesis. Regarding the angiogenic properties of H₂S, Cai and colleagues (2007) reported that intraperitoneal administration of an H₂S donor (NaHS, 10–20 μ mol per kg/day for seven days) increased neovascularization in a mouse model [87]. However, higher concentrations of this H₂S donor in the same assay failed to demonstrate this angiogenic property. This difference might be due to the bell-shaped biological dose-response, with lower doses having a cytoprotective effect, whereas a higher dosage might have a more pronounced cytotoxic effect [89,90].

There are several intracellular signaling pathways that play an important role in the pro-angiogenic effect of H₂S. For instance, vascular endothelial growth factor (VEGF) plays a significant role in the angiogenesis, both in physiology and pathophysiology [91]. Moreover, it has previously been reported that VEGF promotes H₂S synthesis, presumably through calcium/calmodulin-dependent activation of CSE [92]. Other important signaling pathways include the phosphatidylinositol 3-kinase–Akt–survivin

pathway, the extracellular signal-regulated kinase, and p38 pathways [93]. In addition, there is some evidence supporting the role of NO in this process [94], however, its exact implication in disease must be further investigated.

3.2.3. Antioxidant Effect of H₂S

Hydrogen sulfide, in low concentrations, is believed to have a strong antioxidant capacity, which is mainly due to its ROS inhibiting and scavenging property. However, studies on its antioxidant mechanism are limited. Evidence exists indicating that H₂S up-regulates glutathione (GSH) and increases the expression of antioxidant enzymes, such as glutathione peroxidase and superoxide dismutase [95–97]. In addition, H₂S was reported to increase intracellular thioredoxin (Trx-1). This multifunctional molecule not only has ROS scavenging properties, but also plays an important role in cell proliferation [98], apoptosis [99], and gene expression [100]. More recently, increasing evidence revealed that the transcription factor nuclear factor like 2 (Nrf2) may regulate the antioxidant capacity of H₂S by promoting cellular antioxidant gene expression (e.g., glutamate cysteine ligase regulatory subunit, glutamate cysteine ligase catalytic subunit) [101]. This transcription factor can also increase the expression of glutathione reductase, which promotes the recycling of GSH and increases GSH/GSSG ratio, and thereby, reduces oxidative stress [102].

4. The Potential Role of H₂S in the Development of Systemic Sclerosis-Related Vasculopathy

4.1. Link between H₂S and Vascular Injury

The vascular endothelium is considered to be a major target for pathological processes in SSc [7]. Damage to the endothelium is characterized by EC apoptosis, vascular endothelial permeability, and impairment of cell–cell adhesion, which may lead to alterations in EC signal transduction [103]. Collectively, this may lead to endothelial dysfunction, subsequently causing an impaired relaxation of the vessels. Patients often present with RP as the earliest manifestation of this endothelial dysfunction [104].

Homocysteine (Hcy), which is converted into H₂S through the transsulfuration pathway, is considered to be a potential mediator in the initiation of endothelial dysfunction in SSc. It was previously reported that increased levels of Hcy are associated with a higher risk of several cardiovascular diseases, including atherosclerosis, renal, and cerebrovascular diseases [105]. Interestingly, Hcy is also found to be elevated in SSc patients [106–108]. The exact reason for this elevation is unknown. Although the causal relationship between genetic abnormalities and the development of SSc has never been demonstrated, it could be hypothesized that the elevated levels of Hcy may be caused by a defect in the transsulfuration pathway. For instance, Hankey et al. (1999) stated that the most common enzyme defect associated with moderately raised homocysteine level is a point mutation in the coding region of the gene for methylenetetrahydrofolate reductase (MTHFR) [109]. Szamosi et al. (2009) aimed to investigate the prevalence of the MTHFR gene polymorphism in SSc patients [110]. Although they did not demonstrate any differences in Hcy level and MTHFR genotypes, as compared to healthy controls, they did observe significantly higher levels of Hcy in patients with macroangiopathy. Therefore, they concluded that Hcy levels might be associated with the occurrence/development of SSc-related vasculopathy.

Moreover, elevated levels of Hcy can also be caused by a reduced vitamin intake or vitamin deficiency (e.g., folate, vitamin B12, vitamin B6) [111]. This defect could lead to a decreased production of H₂S. A previously conducted experimental animal study in CBS deficient mice showed that *cbs*^{+/-} mice had a normal mean lifespan, and only developed a mild increase in plasma Hcy levels [112]. Moreover, other studies reported that *cbs*^{+/-} and *cbs*^{-/-} mice demonstrate endothelial dysfunction in both large and smaller vessels [113,114]. Hcy is believed to induce an oxidative milieu by stimulating the production of ROS (by the up-regulation of nicotinamide adenine dinucleotide phosphate) [115], and inhibiting antioxidant enzymes (including intracellular glutathione peroxidase) [116–118]. These superoxide anions may react with NO, which leads to the formation of peroxynitrite and a decreased bioavailability of NO, which may further impair the endothelial function [119]. The endothelial dysfunction in

experimental animal studies can be largely attributed to the increase in oxidative stress and decrease of NO bioavailability. In addition, higher levels of Hcy may also lead to a decrease in H₂S production, which is believed to be caused by a decrease in CSE activity. This decrease in CSE activity was previously demonstrated in an experimental animal study in which homocysteine at higher levels reduced CSE activity in rat liver [120]. Moreover, Chang et al. (2008) reported that, although cardiac CSE mRNA expression was up-regulated in the HHcy rats, CSE activity was inhibited by 50% [121]. Furthermore, the administration of H₂S in this animal study slightly lowered Hcy level, decreased myocardial lipid peroxidation, and reduced ROS generation. The decrease in CSE activity may further increase the susceptibility to endothelial injury in SSc patients. The importance of Hcy in the development and perpetuation of endothelial injury is also supported by Caramaschi et al. (2007). They not only observed a higher level of Hcy in SSc patients, as compared to healthy controls, but also demonstrated that the plasma concentration of Hcy is strongly associated with nailfold videocapillaroscopy (NVC) patterns, which is commonly used to assess SSc specific microvascular lesions (Figure 3) [106,122]. This relationship was found to be irrespective of age, RP, SSc duration, the severity of skin involvement and folate levels. These findings are further supported by the observations of Motegi et al. (2014), stating that the plasma concentration of Hcy increases with the progression of nailfold abnormalities [123]. These observations may suggest that even mildly increased levels of Hcy may cause vascular damage in SSc through the direct effect of Hcy on the endothelium, and its inhibitory effect on H₂S production. However, future studies are needed in order to clarify the exact role of Hcy in the occurrence of SSc-related vasculopathy.




Figure 3. Nail-fold capillaroscopy patterns of a healthy subject (A) and a subject with systemic sclerosis (SSc) (B). The images of the nailfolds were taken at 180× magnification.

It has to be noted that the levels of cysteine in healthy individuals are usually higher than the level of homocysteine. Therefore, it could be debated whether the contribution of homocysteine in the production of H₂S is of great importance, in which slight deviations of the norm would lead to impaired H₂S production. However, from a biochemical perspective, during hyperhomocysteinemia, homocysteine may compete with cysteine to bind to CSE, and therefore may indeed decrease H₂S production [124]. Although there is no direct evidence indicating homocysteine induced reduction of CSE activity in SSc patients, a modified CSE activity, as proposed above, may indeed attenuate H₂S generation.

The recurrent vasospastic events, known as RP, cause repetitive and prolonged ischemia followed by reperfusion (I/R injury), and may lead to substantial tissue hypoxia [125]. Some evidence exists indicating that hypoxia can up-regulate the expression of CSE, which may partly protect the cells from hypoxia-induced injury [126]. However, other reports have also shown decreased CSE expression as a result of suppressed expression of the transcription factor specificity protein 1 (Sp1) [127]. These conflicting observations underline the complexity of the role that is played by H₂S in hypoxic conditions. Hydrogen sulfide is also believed to down-regulate hypoxia-inducible factor 1- α

(HIF-1 α) protein levels in cultured cells under hypoxic conditions [128]. This inhibitory effect was achieved with 100 μ M of sodium hydrosulfide (NaHS) or 10 μ M of sodium sulfide (Na₂S).

Vascular injury in SSc may also be the result of impaired angiogenesis. Increasing evidence suggests that an imbalance of pro-angiogenic and anti-angiogenic mediators may be responsible for the impaired angiogenesis [129]. A previously conducted study demonstrated that ECs isolated from SSc patients show an impaired response to VEGF [130]. Hydrogen sulfide is believed to play a significant role in the essential components of the angiogenic response, including the proliferation and migration of endothelial cells. Two studies reported that H₂S leads to an increase of 20% in the proliferation of transformed endothelial cells, and 100% increase in HUVEC cells, in addition to a 30% increase in migration in transformed endothelial cells and a six-fold increase in HUVEC cells [88,93]. The pathways that are involved in these processes have been studied, and H₂S was found to activate PI-3K/Akt axis, enhance the phosphorylation of MAPK pathway, and induce hsp27 phosphorylation [87,88]. Furthermore, it is thought that K_{ATP}-channel opening, more particularly K⁺ efflux, can promote EC motility [88]. In addition, it was previously demonstrated that VEGF increases the production of H₂S, which may subsequently lead to VEGF-induced and H₂S-induced EC migration. A current hypothesis is that both VEGF and H₂S-induced EC migration involve the same downstream pathways, and this assumption is supported by Papapetropoulos et al. (2009), who reported that “VEGF-induced angiogenesis was suppressed in aortic rings of CSE-deficient mice” [88].

4.2. Link between H₂S and Inflammation

Endogenously synthesized H₂S is believed to be an important mediator of inflammation [131], and therefore may play an important role in the pathogenesis of SSc-related vasculopathy. Current literature has provided some conflicting results on the exact role of H₂S in the inflammatory process. For instance, H₂S is thought to have both pro-inflammatory and anti-inflammatory effects. This is presumably due to the biphasic effect of H₂S, with low concentrations inhibiting inflammation and higher concentrations inducing inflammation. The pro-inflammatory effect is thought to be induced by the activation of adenosine triphosphate (ATP)-sensitive K⁺ channels, and this was previously observed in mice with septic shock [132]. The administration of a CSE inhibitor, which decreases the H₂S level, was shown to increase survival in this experimental study [132]. Moreover, in an experimental animal study, Zanardo et al. (2006) demonstrated that H₂S donors inhibit leukocyte adherence during vascular inflammation, which further supports the anti-inflammatory effects of H₂S [133]. In another experimental animal study, the administration of H₂S donors, such as NaSH, was found to induce inflammation through the up-regulation of nuclear factor-kappa B (NF- κ B) and extracellular-signal-regulated kinase (ERK) 1/2 signaling [134]. Furthermore, Rinaldi et al. (2006) found that H₂S prevented apoptosis of human granulocytes via the inhibition of p38 mitogen-activated protein kinases and caspase 3 [135]. Conversely, H₂S is also thought to have several anti-inflammatory effects, including free radical scavenging properties (e.g., peroxynitrite), inhibition of leukocyte adherence to the endothelium [133], and H₂S is believed to reduce the leukocyte infiltration [136,137].

4.3. Link between H₂S and Fibrosis

Hyperhomocysteinemia might be a contributing factor in the increased production of collagen in SSc patients [138]. Hyperhomocysteinemia-induced oxidative stress is thought to be a key player in this process. During this process, matrix metallo-proteinases (MMPs) are believed to be activated, which subsequently cause disturbances in the metabolism of extracellular matrix (ECM). Moreover, Hcy is believed to lead to vascular stiffness by regulating the elastin/collagen ratio [139]. As increased levels of Hcy are known to decrease the CSE activity, it could be postulated that hyperhomocysteinemia leads to a decreased production of H₂S, which may further sustain the pro-fibrotic state [121]. Conversely, hydrogen sulfide itself is believed to have several anti-fibrotic effects. For instance, H₂S is thought to inhibit myofibroblast activation, which is a key event in the pathogenesis of fibrosis in SSc [140]. In addition, the anti-inflammatory effect of H₂S (e.g., decreasing the expression of inflammatory

cytokines) is also thought to block/reduce the disease-related pro-fibrotic state. Wang and colleagues demonstrated that NaHS, which is an H₂S donor, inhibits the fibroblast differentiation and attenuates the protein expressions of TGF- β 1 [141]. In support, several others have concluded “that organ fibrosis might be associated with H₂S deficiency” [142,143]. The blockage of TGF- β 1-induced fibroblast differentiation is presumably achieved through the inhibition of the phosphorylation of Smad3 and mitogen-activated protein kinases [144]. Furthermore, ROS are also thought to play a crucial role in the formation of fibrosis in SSc patients [8]. Hydrogen sulfide has been demonstrated to have ROS-scavenging properties, and thereby eliminates the fibrosis-inducing properties of ROS. Moreover, it was previously shown that the administration of an H₂S donor can lead to the increased expression of antioxidant enzymes (e.g., manganese superoxide dismutase, catalase, and copper-zinc superoxide dismutase), which reduces the oxidative milieu [145]. These findings are further supporting the suggestion that H₂S might play a pivotal role in the pathogenesis of SSc-related vasculopathy.

5. Hydrogen Sulfide as a Therapeutic Option

Exogenous alterations of H₂S levels can be done in several ways, including, but not limited to, treatment with sulfide-sodium salts, exposure to gaseous H₂S, slow-releasing H₂S donors, and by improving the endogenously produced H₂S (e.g., up-regulating the expression of H₂S-producing enzymes) [146]. It was not until the last couple of decades that the perception of H₂S shifted and its important functions were recognized. Following this shift in perception, multiple studies have demonstrated the cytoprotective effects of H₂S [136,137]. In particular, some have demonstrated that H₂S, in relatively low concentrations, can up-regulate endogenous antioxidant systems, increase the production of cAMP, and can up-regulate anti-inflammatory and cytoprotective genes [147]. In contrast to lower concentrations, a higher concentration of H₂S is believed to be cytotoxic, which is likely due to its ability to inhibit cytochrome *c* oxidase. The inhibition of cytochrome *c* oxidase in complex V leads to a decrease in ATP production, and in the presence of oxygen it may lead to the formation of ROS [148]. Moreover, the generation of ROS, glutathione depletion, and the induction of mitochondrial cell death pathways may also enhance or even induce an oxidative milieu [149]. Although studies in SSc patients are lacking, several experimental animal and human studies in other vascular conditions have clearly demonstrated the beneficial effect of H₂S treatment [74,150–152].

5.1. Hydrogen Sulfide in Experimental Animal Studies

Sulfide salts (e.g., Na₂S and NaHS) have previously been used in numerous studies and demonstrated to have protective effects in a variety of diseases, including I/R-related diseases [153]. For instance, Zhang et al. (2013) demonstrated that preconditioning with NaHS reduced the I/R-induced hepatic injury in mice. They stated that the protective effect was presumably achieved by the inhibition of mitochondrial permeability transition pore (mPTP) opening [154]. Johansen et al. (2006) were the first to demonstrate the cytoprotective effect of H₂S following myocardial I/R injury [155]. They reported that NaHS treatment (1 μ M) 10 min prior to reperfusion led to a reduction of the infarct size of 20%. Following their results, several others reported supporting results. For instance, in a recently conducted study, researchers found that injection with Na₂S (compared to vehicle) prior to the ischemia limited the extent of myocardial damage following I/R [156]. Moreover, they demonstrated that this sulfide salt reduced oxidative stress and apoptosis, increased the nuclear accumulation of Nrf2, increased the expression of Trx1 and HO-1, and activated the PKC ϵ -p44/42-STAT-3 pro-survival signaling pathway [156]. Comparable results were found when NaHS was injected one day prior to the myocardial infarction (MI) [157]. NaHS not only reduced the myocardial infarct size, but also prevented apoptosis of cardiomyocyte. However, NaSH that was administered five days prior to MI had no effect.

It was previously proposed that H₂S might also have beneficial effects in renal IR injury. A previously conducted study demonstrated that topical treatment of NaHS on the kidneys 15 min prior to ischemia significantly increased the kidney function [158]. Another study reported that,

during I/R, the renal injury is caused by a reduction in the CBS activity [159]. This finding may suggest that H_2S may be hampered during I/R injury. Furthermore, subtoxic concentrations of H_2S can induce a hibernation-like state in mice [160,161]. It was previously reported that mice, treated with gaseous hydrogen sulfide, showed a reduction of >90% in metabolic rate, and a decline in core body temperature to near ambient temperature. Moreover, H_2S is also known to modulate the blood pressure, and, therefore, it may serve as an add-on treatment option in hypertension. In various experimental mice models, H_2S was found to reduce the arterial pressure after systemic treatment with NaHS [162,163] or after local treatment [164]. These findings are supported by Huang et al. (2015), they stated that NaHS reduced systolic pressure in Dahl rats with high salt-induced hypertension [165].

It has become increasingly clear that H_2S is also abundantly produced by gut microbiota through sulfate-reducing bacteria. Sulfate-reducing bacteria are a non-enzymatic source of H_2S , and several bacteria (e.g., *E. coli*, *Salmonella*, and *Enterobacter*) are known to have the ability to produce H_2S [166]. It was previously shown that antibiotic treatment aimed at reducing the intestinal microbiota resulted in a significant reduction of thiosulfate levels [167]. This finding sheds light on sulfate-reducing bacteria as a therapeutic target in various vascular diseases [166].

The only SSc-resembling experimental animal study was conducted by Wang and colleagues (2016), who investigated the effect of NaHS (56 and 112 $\mu\text{g/kg}$) in an experimental scleroderma-like animal study in mice [141]. They demonstrated that the plasma H_2S levels were decreased in mice after injection with bleomycin. Moreover, they stated that H_2S exerts an anti-inflammatory effect by the reduction of macrophage recruitment in lung tissues. In addition, they also stated that NaHS attenuates the protein expressions of TGF- β 1, indicating that H_2S also inhibits the fibroblast differentiation and extracellular matrix production. In support, several others have concluded “that organ fibrosis might be associated with H_2S deficiency” [142,143]. These findings are further supporting the suggestion that H_2S can be seen as a promising treatment option in SSc. The hypothetical effects of H_2S treatment in SSc can be seen in Figure 4.




Figure 4. Hypothetical inhibitory and promoting effects of hydrogen sulfide treatment in the vasculature of SSc patients.

5.2. Hydrogen Sulfide in Human Studies

Despite the fact that several experimental animal studies clearly demonstrated the beneficial effects of treatment with sulfide salts, large studies in humans are still lacking. Thereby, the majority of

H₂S-releasing derivatives are not yet used in clinical settings. However, sodium thiosulfate (STS) is the exception, given the fact that this sodium salt is already used in various diseases. For instance, STS is a well-known effective antidote that is used in cyanide intoxication. Moreover, STS was proven to be beneficial as a treatment of cisplatin-induced hearing loss. For instance, an open-label, randomized trial demonstrated that hearing loss was significantly lower in children that were treated with STS, as compared to the control group [168]. Importantly, they also reported that the use of STS was not associated with the occurrence of serious adverse events. Sodium thiosulfate is also used in calciphylaxis in patients with end-stage renal disease [169]. Calciphylaxis is a rare disorder that is characterized by calcification of the tunica media, and it is often associated with high mortality rates. Calciphylaxis is a dreaded complication and it often leads to the ulceration of the extremities and contributes to the development of peripheral arterial disease [170]. This dreaded complication can also occur in SSc and it remains virtually untreatable. Several studies have shown that STS has beneficial effects on cutaneous lesions, with a potentially long-lasting effect (11 months–3 years) [171]. In a multi-centric study of 27 calciphylaxis patients that were treated with STS, 70% of these patients had a complete or partial response [172]. Although these effects are presumably mediated through different pathways as compared to the effects as hypothesized in SSc, these promising results indicate that STS can be safely used in the clinical setting. In our hospital, STS is already in a Phase III clinical trial that is designed to evaluate the effect of sodium thiosulfate compared with placebo treatment, in adjunction to optimal reperfusion therapy for acute MI, on left ventricular ejection fraction.

6. Conclusions

Vasculopathy is the hallmark of SSc and it often leads to severe disability and morbidity. To date, SSc is still associated with increased mortality rates given the fact that effective disease-modifying treatment options are currently unavailable. Hydrogen sulfide donors have previously been proven to have beneficial effects in a variety of diseases. These effects range from ROS scavenging, anti-fibrotic, pro-angiogenic, to vasoactive properties. Although the pathways that are involved in H₂S production have not been clearly investigated in SSc, current data may suggest that the readily available H₂S-donor STS may have a great therapeutic potential. Moreover, given the abundant experience in other diseases, with minimal adverse events reported, this drug could probably be safely administered in SSc. A current hypothesis is that early treatment of SSc with STS may alter or even arrest disease progression. Although future studies are needed in order to investigate this hypothesis, the promising effects of H₂S-based therapeutic targets may encourage further study in SSc.

Author Contributions: A.E.A. collected the references and wrote the first draft of the manuscript. D.J.M. and H.v.G. wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

Acknowledgments: The authors would like to thank Else Koning for her valuable help in the graphical design of the figures.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Leroy, E.C. Scleroderma (Systemic Sclerosis): Classification, Subsets and Pathogenesis. *J. Rheumatol.* **1988**, *15*, 202–205.
2. Denton, C.P.; Khanna, D. Systemic sclerosis. *Lancet* **2017**, *390*, 1685–1699. [[CrossRef](#)]
3. Almeida, C.; Almeida, I.; Vasconcelos, C. Quality of life in systemic sclerosis. *Autoimmun. Rev.* **2015**, *14*, 1087–1096. [[CrossRef](#)]
4. Nikpour, M.; Stevens, W.M.; Herrick, A.L.; Proudman, S.M. Epidemiology of systemic sclerosis. *Best Pract. Res. Clin. Rheumatol.* **2010**, *24*, 857–869. [[CrossRef](#)]
5. Ranque, B.; Mouthon, L. Geoepidemiology of systemic sclerosis. *Autoimmun. Rev.* **2010**, *9*, A311–A318. [[CrossRef](#)]

6. Chiffot, H.; Fautrel, B.; Sordet, C.; Chatelus, E.; Sibilia, J. Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review. *Semin. Arthritis Rheum.* **2008**, *37*, 223–235. [\[CrossRef\]](#)
7. Mostmans, Y.; Cutolo, M.; Giddelo, C.; Decuman, S.; Melsens, K.; Declercq, H.; Vandecasteele, E.; De Keyser, F.; Distler, O.; Guterth, J.; et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. *Autoimmun. Rev.* **2017**, *16*, 774–786. [\[CrossRef\]](#)
8. Abdulle, A.E.; de Koning, M.E.; van der Horn, H.J.; Scheenen, M.E.; Roks, G.; Hageman, G.; Spikman, J.M.; van der Naalt, J. Early Predictors for Long-Term Functional Outcome After Mild Traumatic Brain Injury in Frail Elderly Patients. *J. Head Trauma Rehabil.* **2018**, *33*, E59–E67. [\[CrossRef\]](#)
9. Herrick, A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat. Rev. Rheumatol.* **2012**, *8*, 469–479. [\[CrossRef\]](#)
10. Polhemus, D.J.; Lefer, D.J. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. *Circ. Res.* **2014**, *114*, 730–737. [\[CrossRef\]](#)
11. Mann, B.E.; Motterlini, R. CO and NO in medicine. *Chem. Commun.* **2007**, 4197–4208. [\[CrossRef\]](#)
12. Wang, R. Two's company, three's a crowd: Can H₂S be the third endogenous gaseous transmitter? *FASEB J.* **2002**, *16*, 1792–1798. [\[CrossRef\]](#)
13. Matucci Cerinic, M.; Kahaleh, M.B. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. *Rheumatology* **2002**, *41*, 843–847. [\[CrossRef\]](#)
14. Cotton, S.A.; Herrick, A.L.; Jayson, M.I.V.; Freemont, A.J. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. *J. Pathol.* **1999**, *189*, 273–278. [\[CrossRef\]](#)
15. Allanore, Y.; Borderie, D.; Hilliquin, P.; Hervann, A.; Levacher, M.; Lemaréchal, H.; Ekindjian, O.G.; Kahan, A. Low levels of nitric oxide (NO) in systemic sclerosis: Inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. *Rheumatology* **2001**, *40*, 1089–1096. [\[CrossRef\]](#)
16. Dooley, A.; Gao, B.; Bradley, N.; Abraham, D.J.; Black, C.M.; Jacobs, M.; Bruckdorfer, K.R. Abnormal nitric oxide metabolism in systemic sclerosis: Increased levels of nitrated proteins and asymmetric dimethylarginine. *Rheumatology* **2006**, *45*, 676–684. [\[CrossRef\]](#)
17. Malerba, M.; Radaeli, A.; Ragnoli, B.; Airo', P.; Corradi, M.; Ponticello, A.; Zambruni, A.; Grassi, V. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. *Chest* **2007**, *132*, 575–580. [\[CrossRef\]](#)
18. Takagi, K.; Kawaguchi, Y.; Hara, M.; Sugiura, T.; Harigai, M.; Kamatani, N. Serum nitric oxide (NO) levels in systemic sclerosis patients: Correlation between NO levels and clinical features. *Clin. Exp. Immunol.* **2003**, *134*, 538–544. [\[CrossRef\]](#)
19. Loscalzo, J.; Welch, G. Nitric oxide and its role in the cardiovascular system. *Prog. Cardiovasc. Dis.* **1995**, *38*, 87–104. [\[CrossRef\]](#)
20. Palmer, R.M.J.; Ashton, D.S.; Moncada, S. Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature* **1988**, *333*, 664–666. [\[CrossRef\]](#)
21. Zhao, Y.; Vanhoutte, P.M.; Leung, S.W.S. Vascular nitric oxide: Beyond eNOS. *J. Pharmacol. Sci.* **2015**, *129*, 83–94. [\[CrossRef\]](#)
22. Kröncke, K.D.; Fehsel, K.; Kolb-Bachofen, V. Inducible nitric oxide synthase in human diseases. *Clin. Exp. Immunol.* **1998**, *113*, 147–156. [\[CrossRef\]](#)
23. Marietta, M.A.; Yoon, P.S.; Iyengar, R.; Leaf, C.D.; Wishnok, J.S. Macrophage Oxidation of L-Arginine to Nitrite and Nitrate: Nitric Oxide Is an Intermediate. *Biochemistry* **1988**, *27*, 8706–8711. [\[CrossRef\]](#)
24. Yui, Y.; Hattori, R.; Kosuga, K.; Eizawa, H.; Hiki, K.; Ohkawa, S.; Ohnishi, K.; Terao, S.; Kawai, C. Calmodulin-independent nitric oxide synthase from rat polymorphonuclear neutrophils. *J. Biol. Chem.* **1991**, *266*, 3369–3371.
25. Arnold, W.P.; Mittal, C.K.; Katsuki, S.; Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. *Proc. Natl. Acad. Sci. USA* **1977**, *74*, 3203–3207. [\[CrossRef\]](#)
26. Carvajal, J.A.; Germain, A.M.; Huidobro-Toro, J.P.; Weiner, C.P. Molecular mechanism of cGMP-mediated smooth muscle relaxation. *J. Cell. Physiol.* **2000**, *184*, 409–420. [\[CrossRef\]](#)
27. Sammut, I.A.; Foresti, R.; Clark, J.E.; Exon, D.J.; Vesely, M.J.J.; Sarathchandra, P.; Green, C.J.; Motterlini, R. Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. *Br. J. Pharmacol.* **1998**, *125*, 1437–1444. [\[CrossRef\]](#)

28. Thorup, C.; Jones, C.L.; Gross, S.S.; Moore, L.C.; Goligorsky, M.S. Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial NOS. *Am. J. Physiol.* **1999**, *277*, F882–F889. [[CrossRef](#)]
29. Freedman, R.R.; Girgis, R.; Mayes, M.D. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. *J. Rheumatol.* **1999**, *26*, 2386–2388.
30. Romero, L.I.; Zhang, D.N.; Cooke, J.P.; Ho, H.K.; Avalos, E.; Herrera, R.; Herron, G.S. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. *Vasc. Med.* **2000**, *5*, 147–158. [[CrossRef](#)]
31. Nara, K.; Konno, D.; Uchida, J.; Kiuchi, Y.; Oguchi, K. Protective effect of nitric oxide against iron-induced neuronal damage. *J. Neural Transm.* **1999**, *106*, 835–848. [[CrossRef](#)]
32. O'Donnell, V.B.; Freeman, B.A. Interactions between nitric oxide and lipid oxidation pathways: Implications for vascular disease. *Circ. Res.* **2001**, *88*, 12–21. [[CrossRef](#)]
33. Lind, M.; Hayes, A.; Caprnda, M.; Petrovic, D.; Rodrigo, L.; Kruzliak, P.; Zulli, A. Inducible nitric oxide synthase: Good or bad? *Biomed. Pharmacother.* **2017**, *93*, 370–375. [[CrossRef](#)]
34. Yamamoto, T.; Katayama, I.; Nishioka, K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. *J. Rheumatol.* **1998**, *25*, 314–317.
35. Sud, A.; Khullar, M.; Wanchu, A.; Bamberg, P. Increased nitric oxide production in patients with systemic sclerosis. *Nitric Oxide Biol. Chem.* **2000**, *4*, 615–619. [[CrossRef](#)]
36. Ewing, J.F.; Maines, M.D. Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: Heme oxygenase 2 is not a heat shock protein. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 5364–5368. [[CrossRef](#)]
37. Schipper, H.M. Heme oxygenase-1: Transducer of pathological brain iron sequestration under oxidative stress. *Ann. N. Y. Acad. Sci.* **2004**, *1012*, 84–93. [[CrossRef](#)]
38. Wang, R.; Wu, L. The chemical modification of K(Ca) channels by carbon monoxide in vascular smooth muscle cells. *J. Biol. Chem.* **1997**, *272*, 32804–32809. [[CrossRef](#)]
39. Ndisang, J.; Tabien, H.; Wang, R. Carbon monoxide and hypertension. *J. Hypertens.* **2004**, *22*, 1057–1074. [[CrossRef](#)]
40. Andresen, J.; Shafi, N.; Durante, W.; Bryan, R.J. The effect of carbon monoxide and heme oxygenase inhibitors in cerebral vessels of rats and mice. *Am. J. Physiol. Heart Circ. Physiol.* **2006**, *291*, H223–H230. [[CrossRef](#)]
41. Johnson, F.K.; Johnson, R.A. Carbon monoxide promotes endothelium-dependent constriction of isolated gracilis muscle arterioles. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2003**, *285*, R536–R541. [[CrossRef](#)]
42. Foresti, R.; Hammad, J.; Clark, J.E.; Johnson, T.R.; Mann, B.E.; Friebe, A.; Green, C.J.; Motterlini, R. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. *Br. J. Pharmacol.* **2004**, *142*, 453–460. [[CrossRef](#)]
43. Brouard, S.; Otterbein, L.E.; Anrather, J.; Tobiasch, E.; Bach, F.H.; Choi, A.M.; Soares, M.P. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. *J. Exp. Med.* **2000**, *192*, 1015–1026. [[CrossRef](#)]
44. Kim, H.S.; Loughran, P.A.; Rao, J.; Billiar, T.R.; Zuckerbraun, B.S. Carbon monoxide activates NF- κ B via ROS generation and Akt pathways to protect against cell death of hepatocytes. *AJP Gastrointest. Liver Physiol.* **2008**, *295*, G146–G152. [[CrossRef](#)]
45. Kim, K.M.; Pae, H.O.; Zheng, M.; Park, R.; Kim, Y.M.; Chung, H.T. Carbon monoxide induces heme oxygenase-1 via activation of protein kinase R-like endoplasmic reticulum kinase and inhibits endothelial cell apoptosis triggered by endoplasmic reticulum stress. *Circ. Res.* **2007**, *101*, 919–927. [[CrossRef](#)]
46. Zhou, Z.; Song, R.; Fattman, C.L.; Greenhill, S.; Alber, S.; Oury, T.D.; Choi, A.M.K.; Morse, D. Carbon monoxide suppresses bleomycin-induced lung fibrosis. *Am. J. Pathol.* **2005**, *166*, 27–37. [[CrossRef](#)]
47. Peyton, K.J.; Reyna, S.V.; Chapman, G.B.; Ensenat, D.; Liu, X.M.; Wang, H.; Schafer, A.I.; Durante, W. Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. *Blood* **2002**, *99*, 4443–4448. [[CrossRef](#)]
48. Clark, J.E.; Foresti, R.; Sarathchandra, P.; Kaur, H.; Green, C.J.; Motterlini, R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. *Am. J. Physiol. Heart Circ. Physiol.* **2000**, *278*, H643–H651. [[CrossRef](#)]
49. Choi, Y.K.; Kim, C.K.; Lee, H.; Jeoung, D.; Ha, K.S.; Kwon, Y.G.; Kim, K.W.; Kim, Y.M. Carbon monoxide promotes VEGF expression by increasing HIF-1 α protein level via two distinct mechanisms, translational activation and stabilization of HIF-1 α protein. *J. Biol. Chem.* **2010**, *285*, 32116–32125. [[CrossRef](#)]

50. Kimura, Y.; Goto, Y.-I.; Kimura, H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. *Antioxid. Redox Signal.* **2010**, *12*, 1–13. [[CrossRef](#)]
51. Li, L.; Rose, P.; Moore, P.K. Hydrogen Sulfide and Cell Signaling. *Annu. Rev. Pharmacol. Toxicol.* **2011**, *51*, 169–187. [[CrossRef](#)] [[PubMed](#)]
52. Wallace, J.L.; Wang, R. Hydrogen sulfide-based therapeutics: Exploiting a unique but ubiquitous gasotransmitter. *Nat. Rev. Drug Discov.* **2015**, *14*, 329–345. [[CrossRef](#)] [[PubMed](#)]
53. Hancock, J.T.; Whiteman, M. Hydrogen sulfide and cell signaling: Team player or referee? *Plant Physiol. Biochem.* **2014**, *78*, 37–42. [[CrossRef](#)]
54. Liu, Y.-H.; Lu, M.; Hu, L.-F.; Wong, P.T.-H.; Webb, G.D.; Bian, J.-S. Hydrogen Sulfide in the Mammalian Cardiovascular System. *Antioxid. Redox Signal.* **2012**, *17*, 141–185. [[CrossRef](#)]
55. Kimura, H. Production and Physiological Effects of Hydrogen Sulfide. *Antioxid. Redox Signal.* **2014**, *20*, 783–793. [[CrossRef](#)] [[PubMed](#)]
56. Mikami, Y.; Shibuya, N.; Ogasawara, Y.; Kimura, H. Hydrogen sulfide is produced by cystathionine γ -lyase at the steady-state low intracellular Ca^{2+} concentrations. *Biochem. Biophys. Res. Commun.* **2013**, *431*, 131–135. [[CrossRef](#)] [[PubMed](#)]
57. Kabil, O.; Banerjee, R. Enzymology of H_2S biogenesis, decay and signaling. *Antioxid. Redox Signal.* **2014**, *20*, 770–782. [[CrossRef](#)]
58. Wang, R. The Gasotransmitter Role of Hydrogen Sulfide. *Antioxid. Redox Signal.* **2003**, *5*, 493–501. [[CrossRef](#)]
59. Kolluru, G.K.; Shen, X.; Kevil, C.G. A tale of two gases: NO and H_2S , foes or friends for life? *Redox Biol.* **2013**, *1*, 313–318. [[CrossRef](#)]
60. Richardson, C.J.; Magee, E.A.M.; Cummings, J.H. A new method for the determination of sulphide in gastrointestinal contents and whole blood by microdistillation and ion chromatography. *Clin. Chim. Acta* **2000**, *293*, 115–125. [[CrossRef](#)]
61. Bełtowski, J. Hydrogen sulfide in pharmacology and medicine—An update. *Pharmacol. Rep.* **2015**, *67*, 647–658. [[CrossRef](#)] [[PubMed](#)]
62. Shen, X.; Peter, E.A.; Bir, S.; Wang, R.; Kevil, C.G. Analytical measurement of discrete hydrogen sulfide pools in biological specimens. *Free Radic. Biol. Med.* **2012**, *52*, 2276–2283. [[CrossRef](#)] [[PubMed](#)]
63. Furne, J.; Saeed, A.; Levitt, M.D. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. *AJP Regul. Integr. Comp. Physiol.* **2008**, *295*, R1479–R1485. [[CrossRef](#)]
64. Whiteman, M.; Moore, P.K. Hydrogen sulfide and the vasculature: A novel vasculoprotective entity and regulator of nitric oxide bioavailability? *J. Cell. Mol. Med.* **2009**, *13*, 488–507. [[CrossRef](#)] [[PubMed](#)]
65. Wu, D.; Wang, J.; Li, H.; Xue, M.; Ji, A.; Li, Y. Role of hydrogen sulfide in ischemia-reperfusion injury. *Oxid. Med. Cell. Longev.* **2015**, *2015*, 186908. [[CrossRef](#)]
66. Sabry, Z.I.; Shadarevian, S.B.; Cowan, J.W.; Campbell, J.A. Relationship of dietary intake of sulphur amino-acids to urinary excretion of inorganic sulphate in man. *Nature* **1965**, *206*, 931–933. [[CrossRef](#)] [[PubMed](#)]
67. Houterman, S.; Van Faassen, A.; Ocke, M.C.; Habets, L.H.M.; Van Dieijen-Visser, M.P.; Bueno-de-Mesquita, B.H.; Janknegt, R.A. Is urinary sulfate a biomarker for the intake of animal protein and meat? *Cancer Lett.* **1997**, *114*, 295–296. [[CrossRef](#)]
68. van den Berg, E.; Pasch, A.; Westendorp, W.H.; Navis, G.; Brink, E.J.; Gans, R.O.B.; van Goor, H.; Bakker, S.J.L. Urinary Sulfur Metabolites Associate with a Favorable Cardiovascular Risk Profile and Survival Benefit in Renal Transplant Recipients. *J. Am. Soc. Nephrol.* **2014**, *25*, 1303–1312. [[CrossRef](#)]
69. van den Born, J.C.; Frenay, A.-R.S.; Koning, A.M.; Bachtler, M.; Riphagen, I.J.; Minović, I.; Feelisch, M.; Dekker, M.M.; Bulthuis, M.L.C.; Gansevoort, R.T.; et al. Urinary Excretion of Sulfur Metabolites and Risk of Cardiovascular Events and All-Cause Mortality in the General Population. *Antioxid. Redox Signal.* **2018**. [[CrossRef](#)]
70. Ali, M.Y.; Ping, C.Y.; Mok, Y.-Y.; Ling, L.; Whiteman, M.; Bhatia, M.; Moore, P.K. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? *Br. J. Pharmacol.* **2006**, *149*, 625–634. [[CrossRef](#)]
71. Lim, J.J.; Liu, Y.-H.; Khin, E.S.W.; Bian, J.-S. Vasoconstrictive effect of hydrogen sulfide involves downregulation of cAMP in vascular smooth muscle cells. *Am. J. Physiol. Cell Physiol.* **2008**, *295*, C1261–C1270. [[CrossRef](#)]

72. Kubo, S.; Kurokawa, Y.; Doe, I.; Masuko, T.; Sekiguchi, F.; Kawabata, A. Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. *Toxicology* **2007**, *241*, 92–97. [[CrossRef](#)] [[PubMed](#)]
73. Kiss, L.; Deitch, E.A.; Szabó, C. Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. *Life Sci.* **2008**, *83*, 589–594. [[CrossRef](#)]
74. Holwerda, K.M.; Karumanchi, S.A.; Lely, A.T. Hydrogen sulfide: Role in vascular physiology and pathology. *Curr. Opin. Nephrol. Hypertens.* **2015**, *24*, 170–176. [[CrossRef](#)] [[PubMed](#)]
75. Martelli, A.; Testai, L.; Breschi, M.C.; Lawson, K.; McKay, N.G.; Miceli, F.; Taglialatela, M.; Calderone, V. Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. *Pharmacol. Res.* **2013**, *70*, 27–34. [[CrossRef](#)]
76. Jackson-Weaver, O.; Osmond, J.M.; Riddle, M.A.; Naik, J.S.; Bosc, L.V.G.; Walker, B.R.; Kanagy, N.L. Hydrogen sulfide dilates rat mesenteric arteries by activating endothelial large-conductance Ca^{2+} -activated K^{+} channels and smooth muscle Ca^{2+} sparks. *Am. J. Physiol. Heart Circ. Physiol.* **2013**, *304*, H1446–H1454. [[CrossRef](#)]
77. Nicholls, P.; Kim, J. Sulphide as an inhibitor and electron donor for the cytochrome c oxidase system. *Can. J. Biochem.* **1982**, *60*, 613–623. [[CrossRef](#)]
78. Cooper, C.E.; Brown, G.C. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulfide: Chemical mechanism and physiological significance. *J. Bioenerg. Biomembr.* **2008**, *40*, 533–539. [[CrossRef](#)]
79. Dongó, E.; Beliczai-Marosi, G.; Dybvig, A.S.; Kiss, L. The mechanism of action and role of hydrogen sulfide in the control of vascular tone. *Nitric Oxide Biol. Chem.* **2018**, *81*, 75–87. [[CrossRef](#)]
80. Ahmad, F.U.D.; Sattar, M.A.; Rathore, H.A.; Tan, Y.C.; Akhtar, S.; Jin, O.H.; Pei, Y.P.; Abdullah, N.A.; Johns, E.J. Hydrogen sulphide and tempol treatments improve the blood pressure and renal excretory responses in spontaneously hypertensive rats. *Ren. Fail.* **2014**, 598–605. [[CrossRef](#)]
81. Zhao, X.; Zhang, L.-K.; Zhang, C.-Y.; Zeng, X.-J.; Yan, H.; Jin, H.-F.; Tang, C.-S.; Du, J.-B. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. *Hypertens. Res.* **2008**, *31*, 1619–1630. [[CrossRef](#)] [[PubMed](#)]
82. Van Goor, H.; Van Den Born, J.C.; Hillebrands, J.L.; Joles, J.A. Hydrogen sulfide in hypertension. *Curr. Opin. Nephrol. Hypertens.* **2016**, *25*, 107–113. [[CrossRef](#)]
83. Nagpure, B.V.; Bian, J.-S. Interaction of Hydrogen Sulfide with Nitric Oxide in the Cardiovascular System. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 1–16. [[CrossRef](#)]
84. Hosoki, R.; Matsuki, N.; Kimura, H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem. Biophys. Res. Commun.* **1997**, *237*, 527–531. [[CrossRef](#)] [[PubMed](#)]
85. Andrews, K.L.; Lumsden, N.G.; Farry, J.; Jefferis, A.-M.; Kemp-Harper, B.K.; Chin-Dusting, J.P.F. Nitroxyl: A vasodilator of human vessels that is not susceptible to tolerance. *Clin. Sci.* **2015**, *129*, 179–187. [[CrossRef](#)] [[PubMed](#)]
86. Cortese-Krott, M.M.; Koning, A.; Kuhnle, G.G.C.; Nagy, P.; Bianco, C.L.; Pasch, A.; Wink, D.A.; Fukuto, J.M.; Jackson, A.A.; van Goor, H.; et al. The Reactive Species Interactome: Evolutionary Emergence, Biological Significance, and Opportunities for Redox Metabolomics and Personalized Medicine. *Antioxid. Redox Signal.* **2017**, 684–712. [[CrossRef](#)]
87. Cai, W.J.; Wang, M.J.; Moore, P.K.; Jin, H.M.; Yao, T.; Zhu, Y.C. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. *Cardiovasc. Res.* **2007**, 29–40. [[CrossRef](#)]
88. Papapetropoulos, A.; Pyriochou, A.; Altaany, Z.; Yang, G.; Marazioti, A.; Zhou, Z.; Jeschke, M.G.; Branski, L.K.; Herndon, D.N.; Wang, R.; et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc. Natl. Acad. Sci. USA* **2009**, 21972–21977. [[CrossRef](#)]
89. Szabó, C.; Papapetropoulos, A. Hydrogen sulphide and angiogenesis: Mechanisms and applications. *Br. J. Pharmacol.* **2011**, *164*, 853–865. [[CrossRef](#)] [[PubMed](#)]
90. Holwerda, K.M.; Burke, S.D.; Faas, M.M.; Zsengeller, Z.; Stillman, I.E.; Kang, P.M.; van Goor, H.; McCurley, A.; Jaffe, I.Z.; Karumanchi, S.A.; et al. Hydrogen Sulfide Attenuates sFlt1-Induced Hypertension and Renal Damage by Upregulating Vascular Endothelial Growth Factor. *J. Am. Soc. Nephrol.* **2014**, *25*, 717–725. [[CrossRef](#)]
91. Folkman, J. Angiogenesis: An organizing principle for drug discovery? *Nat. Rev. Drug Discov.* **2007**. [[CrossRef](#)] [[PubMed](#)]

92. Coletta, C.; Papapetropoulos, A.; Erdelyi, K.; Olah, G.; Modis, K.; Panopoulos, P.; Asimakopoulou, A.; Gero, D.; Sharina, I.; Martin, E.; et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc. Natl. Acad. Sci. USA* **2012**. [[CrossRef](#)] [[PubMed](#)]
93. Wang, M.-J.; Cai, W.-J.; Zhu, Y.-C. Mechanisms of angiogenesis: Role of hydrogen sulphide. *Clin. Exp. Pharmacol. Physiol.* **2010**, *37*, 764–771. [[CrossRef](#)]
94. Geng, B.; Cui, Y.; Zhao, J.; Yu, F.; Zhu, Y.; Xu, G.; Zhang, Z.; Tang, C.; Du, J. Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2007**, *293*, R1608–R1618. [[CrossRef](#)]
95. Ono, K.; Akaike, T.; Sawa, T.; Kumagai, Y.; Wink, D.A.; Tantillo, D.J.; Hobbs, A.J.; Nagy, P.; Xian, M.; Lin, J.; et al. Redox chemistry and chemical biology of H₂S, hydropersulfides, and derived species: Implications of their possible biological activity and utility. *Free Radic. Biol. Med.* **2014**, *77*, 82–94. [[CrossRef](#)]
96. Predmore, B.L.; Lefer, D.J.; Gojon, G. Hydrogen Sulfide in Biochemistry and Medicine. *Antioxid. Redox Signal.* **2012**, *17*, 119–140. [[CrossRef](#)]
97. Xie, Z.-Z.; Liu, Y.; Bian, J.-S. Hydrogen Sulfide and Cellular Redox Homeostasis. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 6043038. [[CrossRef](#)] [[PubMed](#)]
98. Chutkow, W.A.; Lee, R.T. Thioredoxin regulates adipogenesis through thioredoxin-interacting protein (Txnip) protein stability. *J. Biol. Chem.* **2011**, *286*, 29139–29145. [[CrossRef](#)]
99. Moreno, M.-L.; Escobar, J.; Izquierdo-Álvarez, A.; Gil, A.; Pérez, S.; Pereda, J.; Zapico, I.; Vento, M.; Sabater, L.; Marina, A.; et al. Disulfide stress: A novel type of oxidative stress in acute pancreatitis. *Free Radic. Biol. Med.* **2014**, *70*, 265–277. [[CrossRef](#)]
100. Luo, Y.; He, F.; Hu, L.; Hai, L.; Huang, M.; Xu, Z.; Zhang, J.; Zhou, Z.; Liu, F.; Dai, Y.S. Transcription factor Ets1 regulates expression of thioredoxin-interacting protein and inhibits insulin secretion in pancreatic β -cells. *PLoS ONE* **2014**, *9*, e99049. [[CrossRef](#)]
101. Gan, L.; Johnson, J.A. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. *Biochim. Biophys. Acta Mol. Basis Dis.* **2014**, *1842*, 1208–1218. [[CrossRef](#)] [[PubMed](#)]
102. Harvey, C.J.; Thimmulappa, R.K.; Singh, A.; Blake, D.J.; Ling, G.; Wakabayashi, N.; Fujii, J.; Myers, A.; Biswal, S. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. *Free Radic. Biol. Med.* **2009**, *46*, 443–453. [[CrossRef](#)]
103. Sgonc, R.; Gruschwitz, M.S.; Dietrich, H.; Recheis, H.; Gershwin, M.E.; Wick, G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. *J. Clin. Investig.* **1996**, *98*, 785–792. [[CrossRef](#)]
104. Herrick, A.L. Pathogenesis of Raynaud's phenomenon. *Revmatologia* **2005**, *13*, 62–65. [[CrossRef](#)] [[PubMed](#)]
105. McCully, K.S. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. *Am. J. Pathol.* **1969**, *56*, 111–128.
106. Caramaschi, P.; Volpe, A.; Canestrini, S.; Bambara, L.M.; Faccini, G.; Carletto, A.; Biasi, D. Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis. *Clin. Rheumatol.* **2007**, *26*, 902–907. [[CrossRef](#)]
107. Caramaschi, P.; Martinelli, N.; Biasi, D.; Carletto, A.; Faccini, G.; Volpe, A.; Ferrari, M.; Scambi, C.; Bambara, L.M. Homocysteine plasma concentration is related to severity of lung impairment in scleroderma. *J. Rheumatol.* **2003**, *30*, 298–304.
108. Marasini, B.; Casari, S.; Bestetti, A.; Maioli, C.; Cugno, M.; Zeni, S.; Turri, O.; Guagnellini, E.; Biondi, M.L. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. *J. Rheumatol.* **2000**, *27*, 2621–2623.
109. Hankey, G.J.; Eikelboom, J.W. Homocysteine and vascular disease. *Lancet* **1999**, *354*, 407–413. [[CrossRef](#)]
110. Szamosi, S.; Csiki, Z.; Szomják, E.; Szolnoki, E.; Szoke, G.; Szekanecz, Z.; Szegedi, G.; Shoenfeld, Y.; Szucs, G. Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: Risk factors for accelerated macrovascular damage? *Clin. Rev. Allergy Immunol.* **2009**, *36*, 145–149. [[CrossRef](#)]
111. Mahalle, N.; Kulkarni, M.V.; Garg, M.K.; Naik, S.S. Vitamin B12 deficiency and hyperhomocysteinemia as correlates of cardiovascular risk factors in Indian subjects with coronary artery disease. *J. Cardiol.* **2013**, *61*, 289–294. [[CrossRef](#)] [[PubMed](#)]

112. Watanabe, M.; Osada, J.; Aratani, Y.; Kluckman, K.; Reddick, R.; Malinow, M.R.; Maeda, N. Mice deficient in cystathionine beta-synthase: Animal models for mild and severe homocyst(e)inemia. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 1585–1589. [[CrossRef](#)] [[PubMed](#)]
113. Eberhardt, R.T.; Forgione, M.A.; Cap, A.; Leopold, J.A.; Rudd, M.A.; Trolliet, M.; Heydrick, S.; Stark, R.; Klings, E.S.; Moldovan, N.I.; et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. *J. Clin. Investig.* **2000**, *106*, 483–491. [[CrossRef](#)] [[PubMed](#)]
114. Jiang, X.; Yang, F.; Tan, H.; Liao, D.; Bryan, R.M.; Randhawa, J.K.; Rumbaut, R.E.; Durante, W.; Schafer, A.I.; Yang, X.; et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. *Arterioscler. Thromb. Vasc. Biol.* **2005**, *25*, 2515–2521. [[CrossRef](#)]
115. Zhang, F.; Slungaard, A.; Vercellotti, G.M.; Iadecola, C. Superoxide-dependent cerebrovascular effects of homocysteine. *Am. J. Physiol.* **1998**, *274 Pt 2*, R1704–R1711. [[CrossRef](#)]
116. Upchurch, G.R.; Welche, G.N.; Fabian, A.J.; Freedman, J.E.; Johnson, J.L.; Keaney, J.F.; Loscalzo, J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. *J. Biol. Chem.* **1997**, *272*, 17012–17017. [[CrossRef](#)]
117. Weiss, N.; Zhang, Y.Y.; Heydrick, S.; Bierl, C.; Loscalzo, J. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 12503–12508. [[CrossRef](#)] [[PubMed](#)]
118. Sawle, P.; Foresti, R.; Green, C.J.; Motterlini, R. Homocysteine attenuates endothelial haem oxygenase-1 induction by nitric oxide (NO) and hypoxia. *FEBS Lett.* **2001**, *508*, 403–406. [[CrossRef](#)]
119. Loscalzo, J. The oxidant stress of hyperhomocyst(e)inemia. *J. Clin. Investig.* **1996**, *98*, 5–7. [[CrossRef](#)]
120. Yao, K. Effects of several unusual sulfur-containing amino acids on rat liver cystathionine-gamma-lyase. *Physiol. Chem. Phys.* **1975**, *7*, 401–408.
121. Chang, L.; Geng, B.; Yu, F.; Zhao, J.; Jiang, H.; Du, J.; Tang, C. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. *Amino Acids* **2008**, *34*, 573–585. [[CrossRef](#)] [[PubMed](#)]
122. Cutolo, M.; Pizzorni, C.; Tuccio, M.; Burrioni, A.; Craviotto, C.; Basso, M.; Serio, B.; Sulli, A. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. *Rheumatology* **2004**, *43*, 719–726. [[CrossRef](#)]
123. Motegi, S.; Toki, S.; Yamada, K.; Uchiyama, A.; Ishikawa, O. Elevated plasma homocysteine level is possibly associated with skin sclerosis in a series of Japanese patients with systemic sclerosis. *J. Dermatol.* **2014**, *41*, 986–991. [[CrossRef](#)]
124. Chiku, T.; Padovani, D.; Zhu, W.; Singh, S.; Vitvitsky, V.; Banerjee, R. H₂S biogenesis by human cystathionine γ -lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. *J. Biol. Chem.* **2009**, *284*, 11601–11612. [[CrossRef](#)] [[PubMed](#)]
125. Beyer, C.; Schett, G.; Gay, S.; Distler, O.; Distler, J.H. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. *Arthritis Res. Ther.* **2009**, *11*, 220. [[CrossRef](#)]
126. Wang, M.; Guo, Z.; Wang, S. Regulation of cystathionine γ -lyase in mammalian cells by hypoxia. *Biochem. Genet.* **2014**, *52*, 29–37. [[CrossRef](#)]
127. Cindrova-Davies, T.; Herrera, E.A.; Niu, Y.; Kingdom, J.; Giussani, D.A.; Burton, G.J. Reduced cystathionine γ -lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: Hydrogen sulfide as a placental vasodilator. *Am. J. Pathol.* **2013**, *182*, 1448–1458. [[CrossRef](#)]
128. Wu, B.; Teng, H.; Yang, G.; Wu, L.; Wang, R. Hydrogen sulfide inhibits the translational expression of hypoxia-inducible factor-1 α . *Br. J. Pharmacol.* **2012**, *167*, 1492–1505. [[CrossRef](#)]
129. Manetti, M.; Guiducci, S.; Ibba-Manneschi, L.; Matucci-Cerinic, M. Impaired Angiogenesis in Systemic Sclerosis: The Emerging Role of the Antiangiogenic VEGF165b Splice Variant. *Trends Cardiovasc. Med.* **2011**, *21*, 204–210. [[CrossRef](#)]
130. D'Alessio, S.; Fibbi, G.; Cinelli, M.; Guiducci, S.; Del Rosso, A.; Margheri, F.; Serrati, S.; Pucci, M.; Kahaleh, B.; Fan, P.; et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. *Arthritis Rheum.* **2004**, *50*, 3275–3285. [[CrossRef](#)]
131. Bhatia, M. Role of Hydrogen Sulfide in the Pathology of Inflammation. *Scientifica* **2012**, *2012*, 159680. [[CrossRef](#)] [[PubMed](#)]

132. Li, L.; Bhatia, M.; Zhu, Y.Z.; Zhu, Y.C.; Ramnath, R.D.; Wang, Z.J.; Anuar, F.B.M.; Whiteman, M.; Salto-Tellez, M.; Moore, P.K. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. *FASEB J.* **2005**, *19*, 1196–1198. [[CrossRef](#)] [[PubMed](#)]
133. Zano, R.C.O.; Brancalione, V.; Distrutti, E.; Fiorucci, S.; Cirino, G.; Wallace, J.L. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB J.* **2006**, *20*, 2118–2120. [[CrossRef](#)]
134. Zhang, H.; Mochhala, S.M.; Bhatia, M. Endogenous Hydrogen Sulfide Regulates Inflammatory Response by Activating the ERK Pathway in Polymicrobial Sepsis. *J. Immunol.* **2008**, *181*, 4320–4331. [[CrossRef](#)]
135. Rinaldi, L.; Gobbi, G.; Pambianco, M.; Micheloni, C.; Mirandola, P.; Vitale, M. Hydrogen sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. *Lab. Investig.* **2006**, *86*, 391–397. [[CrossRef](#)] [[PubMed](#)]
136. Whiteman, M.; Armstrong, J.S.; Chu, S.H.; Jia-Ling, S.; Wong, B.S.; Cheung, N.S.; Halliwell, B.; Moore, P.K. The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite “scavenger”? *J. Neurochem.* **2004**, *90*, 765–768. [[CrossRef](#)]
137. Whiteman, M.; Cheung, N.S.; Zhu, Y.Z.; Chu, S.H.; Siau, J.L.; Wong, B.S.; Armstrong, J.S.; Moore, P.K. Hydrogen sulphide: A novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? *Biochem. Biophys. Res. Commun.* **2005**, *326*, 794–798. [[CrossRef](#)]
138. Majors, A.; Ehrhart, L.A.; Pezacka, E.H. Homocysteine as a Risk Factor for Vascular Disease: Enhanced Collagen Production and Accumulation by Smooth Muscle Cells. *Arterioscler. Thromb. Vasc. Biol.* **1997**, *17*, 2074–2081. [[CrossRef](#)]
139. Mayer, O.; Filipovský, J.; Dolejšová, M.; Cífková, R.; Šimon, J.; Bolek, L. Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. *J. Hum. Hypertens.* **2006**, *20*, 267–271. [[CrossRef](#)]
140. Song, K.; Li, Q.; Yin, X.Y.; Lu, Y.; Liu, C.F.; Hu, L.F. Hydrogen sulfide: A therapeutic candidate for fibrotic disease? *Oxid. Med. Cell. Longev.* **2015**, *2015*, 458720. [[CrossRef](#)]
141. Wang, Z.; Yin, X.; Gao, L.; Feng, S.; Song, K.; Li, L.; Lu, Y.; Shen, H. The protective effect of hydrogen sulfide on systemic sclerosis associated skin and lung fibrosis in mice model. *Springerplus* **2016**, *5*, 1084. [[CrossRef](#)]
142. El-Sewaidy, M.M.; Sadik, N.A.H.; Shaker, O.G. Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats. *Arch. Biochem. Biophys.* **2011**, *506*, 48–57. [[CrossRef](#)] [[PubMed](#)]
143. Tan, G.; Pan, S.; Li, J.; Dong, X.; Kang, K.; Zhao, M.; Jiang, X.; Kanwar, J.R.; Qiao, H.; Jiang, H.; et al. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. *PLoS ONE* **2011**, *6*, e25943. [[CrossRef](#)] [[PubMed](#)]
144. Song, K.; Wang, F.; Li, Q.; Shi, Y.B.; Zheng, H.F.; Peng, H.; Shen, H.Y.; Liu, C.F.; Hu, L.F. Hydrogen sulfide inhibits the renal fibrosis of obstructive nephropathy. *Kidney Int.* **2014**, *85*, 1318–1329. [[CrossRef](#)]
145. Jung, K.J.; Jang, H.S.; Kim, J.I.; Han, S.J.; Park, J.W.; Park, K.M. Involvement of hydrogen sulfide and homocysteine transsulfuration pathway in the progression of kidney fibrosis after ureteral obstruction. *Biochim. Biophys. Acta Mol. Basis Dis.* **2013**, *1832*, 1989–1997. [[CrossRef](#)]
146. Bos, E.M.; Van Goor, H.; Joles, J.A.; Whiteman, M.; Leuvenink, H.G.D. Hydrogen sulfide: Physiological properties and therapeutic potential in ischaemia. *Br. J. Pharmacol.* **2015**, *172*, 1479–1493. [[CrossRef](#)]
147. Ryter, S.W.; Alam, J.; Choi, A. Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications. *Physiol. Rev.* **2006**, *86*, 583–650. [[CrossRef](#)] [[PubMed](#)]
148. Szabo, C.; Ransy, C.; Módis, K.; Andriamihaja, M.; Murghes, B.; Coletta, C.; Olah, G.; Yanagi, K.; Bouillaud, F. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. *Br. J. Pharmacol.* **2014**, *171*, 2099–2122. [[CrossRef](#)] [[PubMed](#)]
149. Davies, M.J. The oxidative environment and protein damage. *Biochim. Biophys. Acta Proteins Proteom.* **2005**, *1703*, 93–109. [[CrossRef](#)]
150. Xiao, L.; Dong, J.H.; Jin, S.; Xue, H.M.; Guo, Q.; Teng, X.; Wu, Y.M. Hydrogen Sulfide Improves Endothelial Dysfunction via Downregulating BMP4/COX-2 Pathway in Rats with Hypertension. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 8128957. [[CrossRef](#)]
151. Jin, S.; Teng, X.; Xiao, L.; Xue, H.; Guo, Q.; Duan, X.; Chen, Y.; Wu, Y. Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt/eNOS/NO pathway. *Exp. Biol. Med.* **2017**, *242*, 1831–1841. [[CrossRef](#)]

152. Aghagolzadeh, P.; Radpour, R.; Bachtler, M.; van Goor, H.; Smith, E.R.; Lister, A.; Odermatt, A.; Feelisch, M.; Pasch, A. Hydrogen sulfide attenuates calcification of vascular smooth muscle cells via KEAP1/NRF2/NQO1 activation. *Atherosclerosis* **2017**, *265*, 78–86. [\[CrossRef\]](#) [\[PubMed\]](#)
153. Nicholson, C.K.; Calvert, J.W. Hydrogen sulfide and ischemia-reperfusion injury. *Pharmacol. Res.* **2010**, *62*, 289–297. [\[CrossRef\]](#) [\[PubMed\]](#)
154. Zhang, Q.; Fu, H.; Zhang, H.; Xu, F.; Zou, Z.; Liu, M.; Wang, Q.; Miao, M.; Shi, X. Hydrogen Sulfide Preconditioning Protects Rat Liver against Ischemia/Reperfusion Injury by Activating Akt-GSK-3 β Signaling and Inhibiting Mitochondrial Permeability Transition. *PLoS ONE* **2013**, *8*, 1–12. [\[CrossRef\]](#) [\[PubMed\]](#)
155. Johansen, D.; Ytrehus, K.; Baxter, G.F. Exogenous hydrogen sulfide (H₂S) protects against regional myocardial ischemia-reperfusion injury. Evidence for a role of KATP channels. *Basic Res. Cardiol.* **2006**, *101*, 53–60. [\[CrossRef\]](#)
156. Calvert, J.W.; Jha, S.; Gundewar, S.; Elrod, J.W.; Ramachandran, A.; Pattillo, C.B.; Kevil, C.G.; Lefer, D.J. Hydrogen sulfide mediates cardioprotection through nrf2 signaling. *Circ. Res.* **2009**, *105*, 365–374. [\[CrossRef\]](#) [\[PubMed\]](#)
157. Yao, L.-L.; Huang, X.-W.; Wang, Y.-G.; Cao, Y.-X.; Zhang, C.-C.; Zhu, Y.-C. Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3 β -dependent opening of mPTP. *Am. J. Physiol. Heart Circ. Physiol.* **2010**, *298*, 1310–1319. [\[CrossRef\]](#)
158. Tripatara, P.; Patel, N.S.A.; Collino, M.; Gallicchio, M.; Kieswich, J.; Castiglia, S.; Benetti, E.; Stewart, K.N.; Brown, P.A.; Yaqoob, M.M.; et al. Generation of endogenous hydrogen sulfide by cystathionine γ -lyase limits renal ischemia/reperfusion injury and dysfunction. *Lab. Invest.* **2008**, *88*, 1038–1048. [\[CrossRef\]](#)
159. Xu, Z.; Prathapasinghe, G.; Wu, N.; Hwang, S.-Y.; Siow, Y.L.; O, K. Ischemia-reperfusion reduces cystathionine- β -synthase-mediated hydrogen sulfide generation in the kidney. *Am. J. Physiol.* **2009**, *297*, F27–F35. [\[CrossRef\]](#)
160. Blackstone, E.; Morrison, M.; Roth, M.B. H₂S induces a suspended animation-like state in mice. *Science* **2005**, *308*, 518. [\[CrossRef\]](#)
161. Blackstone, E.; Roth, M.B. Suspended animation-like state protects mice from lethal hypoxia. *Shock* **2007**, *27*, 370–372. [\[CrossRef\]](#) [\[PubMed\]](#)
162. Whiteman, M.; Gooding, K.M.; Whatmore, J.L.; Ball, C.I.; Mawson, D.; Skinner, K.; Tooke, J.E.; Shore, A.C. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. *Diabetologia* **2010**, *53*, 1722–1726. [\[CrossRef\]](#) [\[PubMed\]](#)
163. Sun, L.; Jin, H.; Sun, L.; Chen, S.; Huang, Y.; Liu, J.; Li, Z.; Zhao, M.; Sun, Y.; Tang, C.; et al. Hydrogen sulfide alleviates myocardial collagen remodeling in association with inhibition of TGF- β /Smad signaling pathway in spontaneously hypertensive rats. *Mol. Med.* **2015**, *20*, 503–515. [\[CrossRef\]](#) [\[PubMed\]](#)
164. Sikora, M.; Drapala, A.; Ufnal, M. Exogenous hydrogen sulfide causes different hemodynamic effects in normotensive and hypertensive rats via neurogenic mechanisms. *Pharmacol. Rep.* **2014**, *66*, 751–758. [\[CrossRef\]](#) [\[PubMed\]](#)
165. Huang, P.; Chen, S.; Wang, Y.; Liu, J.; Yao, Q.; Huang, Y.; Li, H.; Zhu, M.; Wang, S.; Li, L.; et al. Down-regulated CBS/H₂S pathway is involved in high-salt-induced hypertension in Dahl rats. *Nitric Oxide Biol. Chem.* **2015**, *46*, 192–203. [\[CrossRef\]](#) [\[PubMed\]](#)
166. Tomasova, L.; Konopelski, P.; Ufnal, M. Gut bacteria and hydrogen sulfide: The new old players in circulatory system homeostasis. *Molecules* **2016**, *21*, 1558. [\[CrossRef\]](#)
167. Tomasova, L.; Dobrowolski, L.; Jurkowska, H.; Wróbel, M.; Huc, T.; Ondrias, K.; Ostaszewski, R.; Ufnal, M. Intracolonic hydrogen sulfide lowers blood pressure in rats. *Nitric Oxide Biol. Chem.* **2016**, *60*, 50–58. [\[CrossRef\]](#)
168. Freyer, D.R.; Chen, L.; Krailo, M.D.; Knight, K.; Villaluna, D.; Bliss, B.; Pollock, B.H.; Ramdas, J.; Lange, B.; Van Hoff, D.; et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* **2017**, *18*, 63–74. [\[CrossRef\]](#)
169. Whiteman, M.; Le Trionnaire, S.; Chopra, M.; Fox, B.; Whatmore, J. Emerging role of hydrogen sulfide in health and disease: Critical appraisal of biomarkers and pharmacological tools. *Clin. Sci.* **2011**, *121*, 459–488. [\[CrossRef\]](#)
170. Cicone, J.S.; Petronis, J.B.; Embert, C.D.; Spector, D.A. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. *Am. J. Kidney Dis.* **2004**, *43*, 1104–1108. [\[CrossRef\]](#)

171. Bourgeois, P.; De Haes, P. Sodium thiosulfate as a treatment for calciphylaxis: A case series. *J. Dermatolog. Treat.* **2016**, *27*, 520–524. [[CrossRef](#)] [[PubMed](#)]
172. Zitt, E.; König, M.; Vychytil, A.; Auinger, M.; Wallner, M.; Lingenhel, G.; Schilcher, G.; Rudnicki, M.; Salmhofer, H.; Lhotta, K. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. *Nephrol. Dial. Transplant.* **2013**, *28*, 1232–1240. [[CrossRef](#)] [[PubMed](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).